Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Assets Average (2022 - 2025)

Zentalis Pharmaceuticals has reported Assets Average over the past 4 years, most recently at $308.1 million for Q4 2025.

  • Quarterly results put Assets Average at $308.1 million for Q4 2025, down 30.05% from a year ago — trailing twelve months through Dec 2025 was $308.1 million (down 30.05% YoY), and the annual figure for FY2025 was $359.7 million, down 26.75%.
  • Assets Average for Q4 2025 was $308.1 million at Zentalis Pharmaceuticals, down from $339.5 million in the prior quarter.
  • Over the last five years, Assets Average for ZNTL hit a ceiling of $603.6 million in Q3 2023 and a floor of $308.1 million in Q4 2025.
  • Median Assets Average over the past 4 years was $514.3 million (2023), compared with a mean of $481.7 million.
  • Biggest five-year swings in Assets Average: increased 14.1% in 2023 and later plummeted 30.05% in 2025.
  • Zentalis Pharmaceuticals' Assets Average stood at $534.3 million in 2022, then rose by 6.45% to $568.7 million in 2023, then dropped by 22.54% to $440.5 million in 2024, then plummeted by 30.05% to $308.1 million in 2025.
  • The last three reported values for Assets Average were $308.1 million (Q4 2025), $339.5 million (Q3 2025), and $367.9 million (Q2 2025) per Business Quant data.